Gatta G, Capocaccia R, Botta L et al (2017) RARECAREnet working group. Burden and centralised treatment in Europe of rare tumours results of RARECAREnet-a population-based study. Lancet Oncol 18:1022–1039

Article  PubMed  Google Scholar 

Fassnacht M, Assie G, Baudin E et al (2020) Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1476–1490

Article  CAS  PubMed  Google Scholar 

Averbuch SD, Steakley CS, Young RC et al (1988) Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109:267–273

Article  CAS  PubMed  Google Scholar 

Niemeijer ND, Alblas G, van Hulsteijn LT et al (2014) Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol 81:642–651

Article  CAS  Google Scholar 

Huang H, Abraham J, Hung E et al (2008) Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113:2020–2028

Article  CAS  PubMed  Google Scholar 

Baudin E, Goichot B, Berruti A et al (2024) Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. Lancet 403:1061–1070

Article  CAS  PubMed  Google Scholar 

Fishbein L, Leshchiner I, Walter V et al (2017) Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31:181–193

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amar L, Bertherat J, Baudin E et al (2005) Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23:8812–8818

Article  CAS  PubMed  Google Scholar 

Neumann HP, Pawlu C, Peczkowska M et al (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943–951

Article  CAS  PubMed  Google Scholar 

Taïeb D, Nölting S, Perrier ND et al (2024) Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement. Nat Rev Endocrinol 20:168–184

Article  PubMed  Google Scholar 

van Nederveen FH, Gaal J, Favier J et al (2009) An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10:764–771

Article  PubMed  PubMed Central  Google Scholar 

Mete O, Pakbaz S, Lerario AM et al (2021) Significance of alpha-inhibin expression in pheochromocytomas and paragangliomas. Am J Surg Pathol 45:1264–1273

Article  PubMed  Google Scholar 

Naing A, Meric-Bernstam F, Stephen B et al (2020) Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8:e000347

Article  PubMed  PubMed Central  Google Scholar 

Tufton N, Hearnden RJ, Berney DM et al (2022) The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas. Endocr Relat Cancer 29:589–598

CAS  PubMed  PubMed Central  Google Scholar 

Celada L, Cubiella T, San-Juan-Guardado J et al (2023) Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype. J Pathol 259:103–114

Article  CAS  PubMed  Google Scholar 

Fujiwara Y, Ohmoto A, Fukuda N et al (2021) Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy. Endocr J 68:671–681

Article  CAS  PubMed  Google Scholar 

Yu A, Xu X, Pang Y et al (2023) PD-L1 Expression is Linked to Tumor-Infiltrating T-Cell Exhaustion and Adverse Pathological Behavior in Pheochromocytoma/Paraganglioma. Lab Invest 103:100210

Article  PubMed  Google Scholar 

Kimura N, Takayanagi R, Takizawa N et al (2014) Phaeochromocytoma Study Group in Japan. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 21:405–414

Article  PubMed  Google Scholar 

Baniak N, Flood TA, Buchanan M et al (2020) Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes. Histopathology 77:659–666

Article  PubMed  Google Scholar 

Shigematsu Y, Amori G, Tanaka K et al (2023) MHC class I loss is associated with biliary/progenitor cell features and “cold” tumor-immune microenvironment in hepatocellular carcinoma. Virchows Arch 483:177–186

Article  CAS  PubMed  Google Scholar 

Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550

Article  CAS  PubMed  Google Scholar 

Shigematsu Y, Inamura K, Yamamoto N et al (2018) Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis. BMC Cancer 18:980

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shigematsu Y, Amori G, Kanda H et al (2022) Decreased ARG1 expression as an adverse prognostic phenotype in non-alcoholic non-virus-related hepatocellular carcinoma. Virchows Arch 481:253–263

Article  CAS  PubMed  Google Scholar 

Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458

Article  CAS  PubMed  Google Scholar 

Li H, Abbas KS, Abdelazeem B et al (2022) A Predictive nomogram for early death in pheochromocytoma and paraganglioma. Front Oncol 12:770958

Article  PubMed  PubMed Central  Google Scholar 

Koh JM, Ahn SH, Kim H et al (2017) Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One 12:e0187398

Article  PubMed  PubMed Central  Google Scholar 

Guo D, Zhao X, Wang A et al (2019) PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas. Hum Pathol 86:155–162

Article  CAS  PubMed  Google Scholar 

Ghosal S, Hadrava Vanova K et al (2023) Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis. Endocrine 79:171–179

Article  CAS  PubMed  Google Scholar 

Goswami KK, Bose A, Baral R (2021) Macrophages in tumor: An inflammatory perspective. Clin Immunol 232:108875

Article  CAS  PubMed  Google Scholar 

Fishbein L, Khare S, Wubbenhorst B et al (2015) Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun 6:6140

Article  CAS  PubMed  Google Scholar 

Calsina B, Piñeiro-Yáñez E, Martínez-Montes ÁM et al (2023) Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma. Nat Commun 14:1122

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Angelo F, Ceccarelli M, Tala, et al (2019) The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat Med 25:176–187

Article